Compare Nutrien Ltd (NTR) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nutrien Ltd vs Pfizer Inc — how do they compare? Nutrien Ltd trades at $67.48 (market cap $33.31B), while Pfizer Inc trades at $28.24 (market cap $158.56B). The key difference: Pfizer Inc is far larger — about 4.8× Nutrien Ltd's market cap, and Pfizer Inc pays the higher dividend (6.18%). Which is the better fit depends on your goals — on Pluang, investors hold Nutrien Ltd for 59 Days and Pfizer Inc for 158 Days on average.
| NTR | PFE | |
|---|---|---|
Market Cap | $33.31B | $158.56B |
Volume | 1,330,729 | 44,138,282 |
Sector | Basic Materials | Health |
52-Week High | $83.94 | $29.02 |
52-Week Low | $53.64 | $23.67 |
Typical Hold Time | 59 Days | 158 Days |
Enterprise Value | $45.11B | $210.06B |
Dividend Yield | 3.15% | 6.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTR trades at $67.48, down 3.56% over 24 hours, with technical indicators showing a bearish trend. The company reported mixed quarterly earnings, missing Q4 2025 and Q2 2026 EPS estimates but beating in Q1 2026. Financials show a net income margin of 8.44% for 2025, with revenue of $26.89B, while recent news highlights industry headwinds from potential U.S. potash deals with Belarus.
The outlook is cautious; analyst consensus is a Moderate Buy with a $76.14 price target, but near-term risks include volatile fertilizer prices and competitive pressures. Long-term demand for agricultural inputs supports fundamentals, yet investors face cyclical earnings and margin compression risks amid macroeconomic uncertainty.
Pfizer (PFE) trades at $28.00, up 1.87% on the day, with a bullish technical signal from moving averages. The company reported revenue of $62.58 billion in 2025 with a net income margin of 6.8%, and has beaten EPS estimates for the last three quarters. Recent news highlights Pfizer's focus on its obesity and oncology pipeline as key growth drivers in 2026.
The stock presents a value opportunity with a consensus price target of $29.17, but faces risks from patent expirations and projected earnings decline. Investor sentiment is mixed, with analysts largely neutral, emphasizing the stock's defensive cash flow and dividend yield amid ongoing business transformation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nutrien Ltd
Created in 2018 as a result of the merger between PotashCorp and Agrium, Nutrien is the world's largest fertilizer producer by capacity. Nutrien produces the three main crop nutrients--nitrogen, potash, and phosphate--although its main focus is potash, where it is the global leader in installed capacity with roughly 20% share. The company is also the largest agricultural retailer in the United States, selling fertilizers, crop chemicals, seeds, and services directly to farm customers through its brick-and-mortar stores and online platforms.
Read more on NTR →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
